SCHEMBL636137

SCHEMBL636137

O=C(/C=C/c1cccc(O)c1O)c1cccc(O)c1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.74
NR1H4 Q96RI1 2/20 0.68
IAPP P10997 4/20 0.64
BCHE P06276 1/20 0.64
GUSB P08236 1/20 0.64
CYP1A1 P04798 1/20 0.59
CYP1B1 Q16678 1/20 0.59
MAOB P27338 2/20 0.57
CHRNA7 P36544 4/20 0.55
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.53
MAPT P10636 1/20 0.53
ALOX12 P18054 1/20 0.53
NFKB1 P19838 1/20 0.53
HTT P42858 1/20 0.53
NFKB2 Q00653 1/20 0.53
KMT2A Q03164 1/20 0.53
RELA Q04206 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL471832 0.91 BCHE (0.77) BACE1NR1H4IAPPBCHEGUSB
SCHEMBL1159948 0.90 BACE1 (0.61) BACE1NR1H4IAPPBCHEGUSB
SCHEMBL11360766 0.87 BACE1 (0.62) BACE1NR1H4IAPPBCHEGUSB
SCHEMBL11360764 0.87 BACE1 (0.62) BACE1NR1H4IAPPBCHEGUSB
SCHEMBL9693070 0.85 BACE1 (0.61) BACE1NR1H4IAPPBCHEGUSB
SCHEMBL4970085 0.82 BACE1 (0.64) BACE1NR1H4IAPPCHRNA7MAPT
SCHEMBL7861935 0.81 NR1H4 (0.74) BACE1NR1H4CYP1A1CYP1B1MAOB
SCHEMBL1073514 0.81 IAPP (0.62) BACE1IAPPBCHEGUSBCYP1B1
SCHEMBL7925826 0.81 IAPP (0.62) BACE1IAPPBCHEGUSBCYP1B1
SCHEMBL30872967 0.81 IAPP (0.62) BACE1IAPPBCHEGUSBCYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108498412-B Fat-soluble glabridin compound whitening agent and application thereof 亿利耐雀生物科技有限公司 2021-07-09 CN claimed
WO-2021053513-A1 METHODS AND MICROORGANISMS FOR PRODUCING FLAVONOIDS ELESZTO GENETIKA, INC. (US) 2021-03-25 WO claimed
EP-2875359-A2 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS Charles R Drew University of Medicine and Science (US) 2015-05-27 EP claimed
WO-2013149258-A2 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS Charles Drew University of Medicine and Science (US) 2013-10-03 WO claimed
US-8367121-B2 Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease FLORIDA A & M UNIVERSITY (US) 2013-02-05 US claimed
EP-2027279-B1 Phenolic compounds with cosmetic and therapeutic applications LIBRAGEN (FR) 2012-04-18 EP claimed
US-20100150895-A1 Nutraceutical agent for attenuating the Neurodegenerative process associated with Parkinson's disease NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-06-17 US claimed
EP-2027279-A2 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES Libragen (FR) 2009-02-25 EP claimed
US-20080292607-A1 Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease MAZZIO ELIZABETH 2008-11-27 US claimed
WO-2007144368-A2 WATER SOLUBLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS LIBRAGEN (FR) 2007-12-21 WO claimed
US-20070208087-A1 Compounds, compositions and methods for the treatment of inflammatory diseases PROTEOTECH INC. 2007-09-06 US claimed
US-20070116779-A1 Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease MAZZIO ELIZABETH 2007-05-24 US claimed
US-20050289662-A1 Reporter system for plants ARESA BIODETECTION APS (DK) 2005-12-29 US claimed
EP-1511847-A1 REPORTER SYSTEM FOR PLANTS Aresa Biodetection Aps (DK) 2005-03-09 EP claimed
WO-2003100068-A1 REPORTER SYSTEM FOR PLANTS ARESA BIODETECTION APS (DK) 2003-12-04 WO claimed
WO-2003013554-A2 AROMATASE INHIBITORS FROM BROUSSONETIA PAPYRIFERA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2003-02-20 WO claimed
US-5109025-A Use of 2',3,4,4'-tetrahydroxychalcone (butein) DAINIPPON INK AND CHEMICALS, INC. (JP) 1992-04-28 US claimed
CN-119432884-A Polygonatum cyrtonema PcOMT gene and application thereof in promotion of high isoflavone synthesis and methylation 浙江农林大学 2025-02-14 CN disclosed
US-5109025-A Use of 2',3,4,4'-tetrahydroxychalcone (butein) DAINIPPON INK AND CHEMICALS, INC. (JP) 1992-04-28 US disclosed
EP-0399051-A1 POLYVALENT ANTIINFLAMMATORY AGENT DAINIPPON INK AND CHEMICALS, INC. (JP) 1990-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208087-A1 Compounds, compositions and methods for the treatment of inflammatory diseases NR1H2, NR1H3, NR1H4 BACE1 455/4885NR1H4 3/4885IAPP 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.